Business Context and Reporting Period
This Form 8-K Current Report was filed by Actinium Pharmaceuticals, Inc. on June 5, 2015, covering events occurring on June 4, 2015. The Company is a Delaware corporation focused on developing radiopharmaceuticals.
Key Financial Metrics
This filing reports a specific capital raising event rather than periodic financial performance. Key metrics include:
- Offering Size: Approximately $5 million in gross proceeds.
- Shares Issued: 1,923,078 shares of common stock.
- Price Per Share: $2.60.
- Expected Closing Date: On or about June 9, 2015.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity as this is a transactional report, not a financial statement.
Material Changes
The primary material change is the entry into subscription agreements for a registered direct offering. This transaction increases the Company's share count and is expected to provide immediate liquidity upon closing.
Guidance, Outlook, and Management Commentary
Management intends to use the net proceeds for general corporate purposes, specifically:
- Capital expenditures.
- Advancement of product candidates in clinical trials, including Iomab-B and Actimab-A.
- Preclinical trials.
- Licensing activities.
- Meeting working capital needs.
Laidlaw & Company (UK) Ltd. acted as the sole placement agent. The offering is subject to customary closing conditions.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds received after deducting placement agent fees and expenses.
- Confirm the updated total share count and potential dilution impact on existing shareholders.
- Review the specific terms of the Placement Agent Agreement (Exhibit 10.1) for fee structures.
- Monitor subsequent filings for the allocation of funds to the specific clinical trials mentioned (Iomab-B and Actimab-A).